GlassScriptPhysician profile
Guy J Angella
NPI 1134116551
$1,791.90
in general payments reported to CMS, 2019-2025
26 companies · $378 in 2025
The $378 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $78.60 · 2021: $89.60 · 2022: $423 · 2023: $303 · 2024: $392 · 2025: $378.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,073.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,072.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $360.56 | 2022-2025 | Alphagan P, Lumigan, Vuity |
| Sight Sciences, INC. | $233.60 | 2022 | |
| Eyepoint US, INC. | $137.50 | 2023 | |
| Bausch & Lomb Americas INC. | $126.76 | 2022-2025 | Envista Mx60 Iol, Stellaris, Vyzulta |
| Mallinckrodt Hospital Products INC. | $107.40 | 2025 | Acthar |
| Horizon Therapeutics Plc | $103.68 | 2022 | |
| Astellas Pharma US INC | $60.51 | 2023 | |
| Allergan, INC. | $56.78 | 2020-2021 | |
| Genentech USA, INC. | $54.85 | 2024-2025 | Vabysmo |
| Medtronic Vascular, INC. | $54.48 | 2019 | |
| Harrow Eye, LLC | $50.00 | 2024 | Vevye |
| Aerie Pharmaceuticals, INC. | $46.54 | 2019-2021 | |
| Ocular Therapeutix, INC. | $45.29 | 2021-2023 | Dextenza |
| Amgen INC. | $41.11 | 2025 | Tepezza |
| Alcon Vision LLC | $41.01 | 2024 | Rocklatan |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $40.10 | 2020-2022 | |
| Johnson & Johnson Surgical Vision, INC. | $37.30 | 2019-2021 | |
| Thea Pharma INC. | $35.49 | 2024 | Iyuzeh |
| Rxsight INC | $34.40 | 2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Tarsus Pharmaceuticals, INC. | $26.95 | 2024 | Xdemvy |
| Omeros Corporation | $22.50 | 2019 | |
| Neurotech Pharmaceuticals, INC. | $21.57 | 2025 | |
| Eyevance Pharmaceuticals LLC | $20.19 | 2020 | |
| Akorn, INC. | $19.26 | 2019 | |
| Oyster Point Pharma, INC. | $14.07 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$249,693.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Angella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.